OrthoPediatrics (KIDS - Free Report) reported $39.97 million in revenue for the quarter ended September 2023, representing a year-over-year increase of 14.4%. EPS of -$0.13 for the same period compares to -$0.05 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $40.26 million, representing a surprise of -0.72%. The company delivered an EPS surprise of +35.00%, with the consensus EPS estimate being -$0.20.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how OrthoPediatrics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product sales by category- Trauma and deformity: $28.81 million versus the three-analyst average estimate of $27.68 million. The reported number represents a year-over-year change of +20.5%.
- Product sales by category- Sports medicine/other: $0.86 million versus the three-analyst average estimate of $1.19 million. The reported number represents a year-over-year change of -21.6%.
- Product sales by category- Scoliosis: $10.30 million versus $11.17 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3% change.
View all Key Company Metrics for OrthoPediatrics here>>>Shares of OrthoPediatrics have returned -8.3% over the past month versus the Zacks S&P 500 composite's +3.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
OrthoPediatrics (KIDS - Free Report) reported $39.97 million in revenue for the quarter ended September 2023, representing a year-over-year increase of 14.4%. EPS of -$0.13 for the same period compares to -$0.05 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $40.26 million, representing a surprise of -0.72%. The company delivered an EPS surprise of +35.00%, with the consensus EPS estimate being -$0.20.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how OrthoPediatrics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Product sales by category- Trauma and deformity: $28.81 million versus the three-analyst average estimate of $27.68 million. The reported number represents a year-over-year change of +20.5%.
- Product sales by category- Sports medicine/other: $0.86 million versus the three-analyst average estimate of $1.19 million. The reported number represents a year-over-year change of -21.6%.
- Product sales by category- Scoliosis: $10.30 million versus $11.17 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3% change.
View all Key Company Metrics for OrthoPediatrics here>>>Shares of OrthoPediatrics have returned -8.3% over the past month versus the Zacks S&P 500 composite's +3.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Get the latest research report on KIDS - FREE